Formulary Inclusion

When a product is added to the VA National Formulary, it becomes part of the official list of treatments that VA healthcare providers can prescribe. For ActiPatch and RecoveryRx, this means:

They’re recognized as approved therapies within the VA system.

VA clinicians can routinely prescribe them for pain management.

It streamlines access for veterans—no special approvals or workarounds needed.

This is a huge step toward mainstream adoption in federal healthcare.

Direct Reimbursement

Thanks to the NOPAIN for Veterans Act, these devices are now eligible for direct reimbursement by the VA. That means:

Veterans don’t pay out-of-pocket for these therapies.

BIEL receives payment directly from the government for each device used.

It creates a predictable revenue stream for BIEL, especially as usage scales.

This removes a major barrier to adoption and makes the devices more accessible.

VA Prescribing

VA doctors can now prescribe ActiPatch and RecoveryRx just like any other approved treatment. This opens up:

Widespread clinical use across pain management, orthopedics, physical therapy, and post-op recovery.

Integration into prosthetics programs, where RecoveryRx is already being used for residual limb pain.

A pathway for feedback and data collection from real-world use, which can further validate the technology.

The Big Picture

Together, these three milestones mean BIEL’s devices are:

Officially recognized by the VA

Financially supported by federal reimbursement

Clinically accessible to millions of veterans

It’s a trifecta that positions BIEL for explosive growth in the federal healthcare space.